Developing A Policy For Second-Generation Antipsychotic Drugs-Reference-Cited by-同舟云学术

Developing A Policy For Second-Generation Antipsychotic Drugs

Published:2009-01 Issue:Supplement 1 Volume:28 Page:w782-w793
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Rosenheck Robert A.¹,Sernyak Michael J.¹

Affiliation:

1. Robert Rosenheck () is codirector of the New England Mental Illness Research, Education, and Clinical Center, Veterans Affairs (VA) Connecticut Health Care System, in West Haven. Michael Sernyak is chief of the Mental Health Service, Psychiatry, at the VA Connecticut Health Care System.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference45 articles.

1. The Economic Burden of Schizophrenia in the United States in 2002

2. Special Section on Implications of CATIE: Who Are the New Users of Antipsychotic Medications?

3. Do new prescription drugs pay for themselves?

4. Special Section on Implications of CATIE: Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making

5. Special Section on Implications of CATIE: Policy Toward Second-Generation Antipsychotic Drugs: A Cautionary Note

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Victimization in schizophrenia and its relation to violence;Schizophrenia Research;2023-05

2. Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration;Trials;2023-02-06

3. Risk and protective factors of relapse in patients with first-episode schizophrenia from perspectives of health professionals: a qualitative study in northeastern Thailand;F1000Research;2021-06-25

4. An 18-month longitudinal study of suicidality in patients diagnosed with schizophrenia;Schizophrenia Research;2020-10

5. Mental health multimorbidity and poor quality of life in patients with schizophrenia;Schizophrenia Research;2018-11